证券代码：600352 股票简称：浙江龙盛 公告编号：2023-046 号 浙江龙盛集团股份有限公司 关于 2023 年度第十二期超短期融资券(科创票据) 发行结果的公告 公司于2023年9月20日发行2023年度第十二期超短期融资券(科创票据)，发 行结果如下： | | 浙江龙盛集团股份有限公司 | | | | | | 23 龙盛 SCP012 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 2023 年度第十二期超短期融资券 简称 (科创票据) | | | | | | (科创票据) | | | | | | 代码 | 012383533 期限 | | | | | | 180 | | 日 | | | | 发行日 | 2023 9 月 | 年 | | 20 | 日 | 起息日 | 2023 9 | 年 | 月 | 21 | 日 | | 交易流通终止日 | 2024 3 兑付日 | 年 | 月 | 18 | 日 | | 2024 3 | 年 | 月 | 19 | 日 | | 发行总 ...

证券代码：600352 股票简称：浙江龙盛 公告编号：2023-044 号 浙江龙盛集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于 2023 年度第十一期超短期融资券(科创票据) 发行结果的公告 董 事 会 二 O 二三年九月十六日 公司于2022年5月20日召开第九届董事会第二次会议，审议并通过《关于发 行超短期融资券的议案》，具体内容已在2022年5月21日披露于《上海证券报》、 《证券时报》、《证券日报》和上海证券交易所网站 (公告编号：2022-037号和 2022-039号)。中国银行间市场交易商协会于2022年7月20日出具《接受注册通知 书》（中市协注〔2022〕SCP244号），接受公司超短期融资券注册，注册金额为 人民币50亿元，注册额度自该通知书发出之日起2年内有效，具体内容详见2022 年7月23日披露的《关于超短期融资券获得注册的公告》（公告编号：2022-048 号）。 公司于2023年9月14日发行2023年度第十一期超短期融资券(科创票据)，发 行结果如下： | | 浙江龙 ...

特此公告。 浙江龙盛集团股份有限公司 董 事 会 二 0 二三年九月十六日 浙江龙盛集团股份有限公司 2023 年度第二期超短期融资券(科创票据) 兑付完成公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于2023年4月14日在全国银行间债券市场公开发行2023年度第二期超 短期融资券(科创票据)（简称"23龙盛SCP002(科创票据)"，代码"012381536"）， 发行规模5亿元人民币，期限为150日，计息方式：零息利率，兑付日：2023年9 月14日，发行价格为100元/百元面值，票面利率为2.84%。具体内容详见2023年4 月19日披露的《关于2023年度第二期、第三期、第四期超短期融资券(科创票据) 发行结果的公告》（公告编号：2023-022号）。 2023年9月14日，公司已兑付2023年度第二期超短期融资券(科创票据)本息 合计人民币505,737,704.92元，由银行间市场清算所股份有限公司代理划付至债 券持有人。 证券代码：600352 证券简称：浙江龙盛 公告编号：2023-043 号 ...

证券代码：600352 股票简称：浙江龙盛 公告编号：2023-042 号 浙江龙盛集团股份有限公司 关于 2023 年度第十期超短期融资券(科创票据) 发行结果的公告 上 述 超 短 期 融 资 券 发 行 的 相 关 文 件 已 在 中 国 货 币 网 （www.chinamoney.com.cn）和上海清算所网站（www.shclearing.com.cn）披露。 特此公告。 浙江龙盛集团股份有限公司 董 事 会 二 O 二三年九月九日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于2022年5月20日召开第九届董事会第二次会议，审议并通过《关于发 行超短期融资券的议案》，具体内容已在2022年5月21日披露于《上海证券报》、 《证券时报》、《证券日报》和上海证券交易所网站 (公告编号：2022-037号和 2022-039号)。中国银行间市场交易商协会于2022年7月20日出具《接受注册通知 书》（中市协注〔2022〕SCP244号），接受公司超短期融资券注册，注册金额为 人民币50亿元，注册额度自该通知书发出 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥7,219,257,528.71, a decrease of 20.45% compared to ¥9,074,695,768.00 in the same period last year[13]. - The net profit attributable to shareholders for the first half of 2023 was ¥792,413,099.69, down 44.38% from ¥1,424,746,844.43 in the previous year[14]. - The basic earnings per share for the first half of 2023 were ¥0.2511, a decrease of 42.76% from ¥0.4387 in the same period last year[15]. - The weighted average return on net assets decreased to 2.44%, down 2.16 percentage points from 4.60% in the previous year[15]. - The decline in net profit and earnings per share was primarily due to a decrease in product sales and prices, leading to a drop in profit margins[16]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was 812 million RMB, a decline of 29.89% year-on-year[22]. - The company achieved operating revenue of 7.219 billion RMB, a year-on-year decrease of 20.45%[22]. - The company reported a total comprehensive income of CNY 993,745,383.36, down 43.7% from CNY 1,765,219,558.78 in the same period of 2022[92]. Cash Flow and Assets - The net cash flow from operating activities significantly increased to ¥3,267,672,274.83, compared to ¥118,056,355.62 in the same period last year, marking a rise of 2,667.89%[14]. - Cash and cash equivalents increased by 82.11% to ¥12,519,498,710.70 from ¥6,874,503,308.48 year-on-year[27]. - The total assets at the end of the reporting period were ¥69,979,820,001.49, reflecting a 7.39% increase from ¥65,161,739,457.60 at the end of the previous year[14]. - The company reported a total cash balance of CNY 12,519,498,710.70 at the end of the period, up from CNY 6,874,503,308.48 at the beginning of the period, indicating a significant increase of approximately 82%[183]. Investments and R&D - The company is focusing on internal R&D and external acquisitions to enrich its product line and expand market share[21]. - Research and development expenses decreased by 25.20% to ¥277,601,822.05 from ¥371,119,787.32 year-on-year[24]. - The company is investing $30 million in research and development for new technologies aimed at enhancing product efficiency[174]. Environmental Management - The company is implementing a "zero emissions" management concept in its production processes[21]. - The company emphasizes safety in its chemical operations, implementing improvements based on the DuPont sustainable solutions to enhance safety management[37]. - The company has established a comprehensive environmental management system to monitor and control emissions across its operations[45]. - The company has committed to not engaging in competitive activities that conflict with its business operations, ensuring compliance from major shareholders[55]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 166,733[67]. - The top ten shareholders held a combined 37.32% of the company's shares, with the largest shareholder holding 11.98%[68]. - The company has no significant changes in share capital structure during the reporting period[66]. Risk Management - The company faces management risks due to the increasing number of subsidiaries, necessitating enhanced oversight and internal auditing to prevent mismanagement[38]. - The company is exposed to foreign exchange risks due to operations in multiple currencies, but currently employs natural hedging methods to manage this risk[38]. - The company has a structured approach to risk management, prioritizing safety and environmental considerations in its operations[37]. Legal and Compliance - The company has not reported any significant litigation or arbitration matters during the reporting period[57]. - The company and its subsidiaries are involved in a patent infringement lawsuit, with a claim for economic damages amounting to RMB 230 million, and a court ruling requiring compensation of RMB 14 million and additional costs totaling RMB 3.8 million[58]. Accounting Policies - The financial statements comply with the requirements of the enterprise accounting standards, accurately reflecting the company's financial position and operating results[120]. - The company applies specific accounting treatment for mergers and acquisitions, recognizing goodwill when the purchase cost exceeds the fair value of identifiable net assets acquired[124]. - The company recognizes revenue based on the progress of performance obligations, confirming income when control of goods or services is transferred to the customer[167].

证券代码：600352 证券简称：浙江龙盛 公告编号：2023-039 号 浙江龙盛集团股份有限公司 2023 年上半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号——行业信息披露》的 要求，公司现将 2023 年上半年度主要经营数据披露如下： 注：上述产品销量包含了部分外购成品再销售的量。 二、主要产品和原材料的价格变动情况 0 20,000 40,000 60,000 80,000 100,000 120,000 140,000 2022年第二季度 2022年第三季度 2022年第四季度 2023年第一季度 2023年第二季度 主要产品销售价格波动走势图 分散染料 活性染料 德司达分散 德司达活性 德司达靛蓝 德司达助剂 间苯二胺 间苯二酚 单位：元/吨 （二）主要原料价格(不含增值税)波动情况 第 2 页 共 4 页 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 2022年第二季度 20 ...

证券代码：600352 证券简称：浙江龙盛 公告编号：2023-041 号 2023年8月25日，公司已兑付2023年度第一期超短期融资券(科创票据)本息 合计人民币809,311,475.41元，由银行间市场清算所股份有限公司代理划付至债 券持有人。 特此公告。 浙江龙盛集团股份有限公司 董 事 会 二 0 二三年八月二十六日 浙江龙盛集团股份有限公司 2023 年度第一期超短期融资券(科创票据) 兑付完成公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于2023年3月27日在全国银行间债券市场公开发行2023年度第一期超 短期融资券(科创票据)（简称"23龙盛SCP001(科创票据)"，代码"012381234"）， 发行规模8亿元人民币，期限为150日，计息方式：零息利率，兑付日：2023年8 月25日，发行价格为100元/百元面值，票面利率为2.84%。具体内容详见2023年3 月29日披露的《关于2023年度第一期超短期融资券(科创票据)发行结果的公告》 （公告编号：2023-009号）。 ...

证券代码：600352 证券简称：浙江龙盛 公告编号：2023-040 号 浙江龙盛集团股份有限公司 关于举行 2023 年上半年度网上业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、会议召开时间：2023 年 8 月 31 日下午 15:00—17:00 2、会议召开网址：公司网站（http://www.longsheng.com） 3、会议召开方式：网络平台在线交流 4、投资者可在 2023 年 8 月 31 日 15:00 前通过公司"互动平台"上先提出 所关注的问题，公司将在说明会上选择投资者普遍关注的问题进行回答。 一、说明会类型 公司已于 2023 年 8 月 26 日披露公司《2023 年半年度报告》（刊登在《上海 证券报》、《证券时报》和《证券日报》及上海证券交易所网站）。为便于广大投 资者更全面深入地了解公司生产经营、财务、战略、投资等方面情况，公司决定 通过网络远程的方式举行"2023 年上半年度网上业绩说明会"。 二、说明会召开的时间 会议召开时间：2023 年 8 ...

被担保人名称：公司全资子公司浙江鸿盛化工有限公司（以下简称"浙 江鸿盛"）、浙江安诺芳胺化学品有限公司（以下简称"浙江安诺"）和绍兴市上 虞金冠化工有限公司（以下简称"绍兴金冠"）。 本次担保金额及已实际为其提供的担保余额：公司本次为浙江鸿盛提供 最高额保证，其中在光大银行担保的主债权最高本金余额为人民币 2.5 亿元，在 工商银行担保的最高债权额为人民币 7 亿元；为浙江安诺提供最高额保证，担保 最高债权额为人民币 3.8 亿元；为绍兴金冠提供最高额保证，担保最高债权额为 人民币 4.3 亿元。截至 2023 年 8 月 10 日，公司实际为浙江鸿盛提供担保余额共 计人民币 23.37 亿元，为浙江安诺提供担保余额共计人民币 4.95 亿元，为绍兴 金冠提供担保余额共计人民币 5.61 亿元，上述担保均在股东大会核定的担保额 度范围内。 上述担保均无反担保。 公司不存在逾期担保的情况。 证券代码：600352 证券简称：浙江龙盛 公告编号：2023-037 号 浙江龙盛集团股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥3,748,527,750.79, representing a decrease of 16.80% compared to the same period last year[4] - The net profit attributable to shareholders was ¥343,678,131.76, down 26.81% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥226,692,945.76, a decline of 59.08% compared to the previous year[4] - The company's basic and diluted earnings per share were both ¥0.1089, reflecting a decrease of 24.53% year-on-year[4] - The weighted average return on equity was 1.06%, down by 0.48 percentage points compared to the previous year[4] - Net profit for Q1 2023 was CNY 384,266,803.05, a decline of 29.4% from CNY 544,334,763.28 in Q1 2022[16] - The comprehensive income for Q1 2023 was ¥268,109,395.58, compared to ¥159,144,734.23 in Q1 2022, showing an increase of 68.5%[23] Cash Flow - The net cash flow from operating activities increased significantly by 623.97%, amounting to ¥1,520,648,057.45[4] - In Q1 2023, the company reported a net cash flow from operating activities of CNY 1,520,648,057.45, a significant increase from CNY 210,044,046.67 in Q1 2022, representing a growth of approximately 624%[17] - Total cash inflow from operating activities reached CNY 6,249,345,145.32, compared to CNY 4,420,875,213.08 in the same period last year, marking an increase of about 41.3%[17] - The company’s cash inflow from investment activities was CNY 296,170,858.98, compared to CNY 233,092,376.34 in Q1 2022, showing an increase of about 27.0%[18] - The net cash flow from investment activities was ¥80,281,370.51, recovering from a negative cash flow of -¥511,435,126.43 in Q1 2022, showcasing improved investment returns[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥68,110,636,144.73, an increase of 4.53% from the end of the previous year[5] - The total assets increased to CNY 68,110,636,144.73 in Q1 2023 from CNY 65,161,739,457.60 in Q1 2022, reflecting a growth of 4.5%[14] - The total liabilities increased to CNY 33,083,470,506.44 in Q1 2023 from CNY 30,403,629,011.67 in Q1 2022, representing an increase of 8.8%[14] - The total liabilities decreased to CNY 23,367,284,275.24 from CNY 24,201,065,124.80, showing a reduction of approximately 3%[13] - The total liabilities to equity ratio was approximately 4.07 in Q1 2023, compared to 3.75 in Q1 2022, indicating increased leverage[21] Equity and Investments - The equity attributable to shareholders increased slightly by 0.69% to ¥32,387,761,453.91 compared to the end of last year[5] - The total equity attributable to shareholders of the parent company rose to CNY 32,387,761,453.91 in Q1 2023, up from CNY 32,166,710,058.29 in Q1 2022, an increase of 0.7%[14] - The long-term equity investments were valued at CNY 2,016,979,516.62, down from CNY 2,141,125,749.13, representing a decline of approximately 6%[13] Expenses - Research and development expenses for Q1 2023 were CNY 146,724,345.21, a decrease of 15.2% from CNY 172,976,678.20 in Q1 2022[15] - Financial expenses increased to CNY 102,103,838.37 in Q1 2023, compared to CNY 76,639,521.37 in Q1 2022, marking an increase of 33.2%[15] - The financial expenses in Q1 2023 were ¥69,836,228.29, significantly higher than ¥28,118,661.58 in Q1 2022, indicating an increase of 148.5%[22] Inventory and Receivables - The company's inventory stood at CNY 28,617,753,736.10, slightly down from CNY 28,648,522,837.86, indicating a decrease of about 0.1%[12] - Accounts receivable increased to CNY 2,798,438,924.32 from CNY 2,271,965,047.68, reflecting a growth of approximately 23%[12]